首页> 美国卫生研究院文献>other >MHC Class I Loss is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer that is Reversed by Interferon and Selumetinib Treatment in vitro

【2h】

MHC Class I Loss is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer that is Reversed by Interferon and Selumetinib Treatment in vitro

机译：MHC I类损失是乳头状甲状腺癌免疫逃逸的常见机制该机制在体外被干扰素和Selumetinib治疗逆转

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeTo evaluate Major Histocompatibility Complex (MHC) Class I expression on papillary thyroid cancer (PTC) and analyze changes in MHC expression and associated immune activation with current and experimental treatments for thyroid cancer using in vitro PTC cell lines.

机译：目的评估甲状腺乳头状癌（PTC）上的主要组织相容性复合体（MHC）I类表达，并分析目前和实验中使用体外PTC细胞系对甲状腺癌的MHC表达变化和相关的免疫激活。

著录项

期刊名称 other
作者
Trevor E. Angell; Melissa G. Lechner; Julie K. Jang; Jonathan S. LoPresti; Alan L. Epstein;
展开▼
作者单位

展开▼
年(卷),期 -1(20),23
年度 -1
页码 6034–6044
总页数 20
原文格式 PDF
正文语种
中图分类
关键词
papillary thyroid cancer tumor-infiltrating leukocytes MHC class I interferon selumetinib tumor immunology;

机译：甲状腺乳头状癌;肿瘤浸润性白细胞;MHC I类;干扰素;selumetinib;肿瘤免疫学;

相似文献

外文文献
中文文献
专利

1. MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro [J] . Angell Trevor E., Lechner Melissa G., Jang Julie K., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第23期

机译：MHC I类损失是乳头状甲状腺癌免疫逃逸的常见机制，可通过干扰素和Selumetinib的体外治疗逆转
2. MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro [J] . Angell Trevor E., Lechner Melissa G., Jang Julie K., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第23期

机译：MHC I类损失是乳头状甲状腺癌免疫逃逸的常见机制，可通过干扰素和Selumetinib的体外治疗逆转
3. IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro [J] . Jia-Qian Hu, Bo-Wen Lei, Duo Wen, Journal of Cancer . 2020,第14期

机译：IL-2增强的MHC I类I表达乳头状甲状腺癌与哈希莫氏症的甲状腺炎克服了免疫逃生体外
4. Potential Immune Escape Mechanisms of Tumors: MHC Class I Molecules – Enemies or Friends [C] . Barbara Seliger NATO Advanced Research Workshop on Stem Cells and their Potential for Clinical Application . 2008

机译：肿瘤的潜在免疫逃生机制：MHC I类分子 - 敌人或朋友
5. Unwelcome Guests: Methods of Pathologic Escape from MHC Class I-Mediated Immunity [D] . Khalsa, Harimander. 2020

机译：不受欢迎的客人：来自MHC类I介导的免疫力的病理逃脱方法
6. IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimotos thyroiditis overcomes immune escape in vitro [O] . Jia-Qian Hu, Bo-Wen Lei, Duo Wen, 2020

机译：IL-2增强桥本甲状腺炎的乳头状甲状腺癌中MHC I类表达克服了体外免疫逃逸
7. MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro [O] . Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, 2014

机译：MHC Class I损失是乳头状甲状腺癌免疫逃逸的常见机制，其在体外逆转干扰素和塞卢米替尼治疗

相关主题

MHC Class I Loss is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer that is Reversed by Interferon and Selumetinib Treatment in vitro

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅